Polycystic Ovary Syndrome Genetics and Treatment Response

• Status: Unknown status
• Trial end date: 2019-10-01
• Target enrollment: 0
• Participant gender: Female

Summary

Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in reproductive age women. Women with PCOS have a high risk of prediabetes, type 2 diabetes and heart disease. The investigators have found a possible change in the DNA (genes of the body that encode all of our traits) that seems to be related to insulin resistance. In this study, the investigators will try to determine whether the change in the gene affects a woman's ability to respond to a common treatment for PCOS, metformin.

These studies will uncover the change in a gene that might be one of the causes of PCOS. Discovering this gene will help better understand the diabetes and insulin abnormalities that are common in PCOS and will help us to better diagnose and treat PCOS to prevent the diabetes in these women.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Massachusetts General Hospital
• Collaborator: American Diabetes Association
• Treatments: Metformin

Criteria

Inclusion Criteria:

• Polycystic ovary syndrome

• No medications for 1 month

• Good general health

Exclusion Criteria:

• Smoker

• Acute infection or chronic disease

• Diabetes

• Trying to get pregnant

• Bleeding disorders